In mice, either genetic deficiency of EPHX2 or treatment with a tool EPHX2i have been reported to attenuate chronic active IBD in IL10 (-/-) and in DSS-induced colitis models [13–15]. Here, IL10 is linked to inflammatory bowel disease.